Takefumi Inada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takefumi Inada has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Koh Shingu
Department of Anesthesiology, Kansai Medical University, Osaka, Japan
4 shared publicationsK. Shingu
Department of Anesthesiology, Kansai Medical University, Osaka, Japan
3 shared publicationsMakiko Yamada
Department of Anesthesiology, Kansai Medical University, Osaka, Japan
3 shared publicationsS. Sakamoto
Department of Anesthesiology, Kansai Medical University, Osaka, Japan
2 shared publicationsTakashi Asai
Department of Anesthesiology|Kansai Medical University
2 shared publicationsA. Kushida
Department of Anesthesiology, Kansai Medical University, Osaka, Japan
1 shared publication
Latest Publications
- 14 March 2007
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 51 (4) , 490-494
Intrathecal betamethasone pain relief in cancer patients with vertebral metastasis: a pilot study*
Background: We have reported previously the usefulness of intrathecal betamethasone for pain relief in cancer patients who suffer from intractable pain caused by vertebral metastasis. The mechanism by which betamethasone relieves pain may be related to alterations in cerebrospinal fluid (CSF) concentrations of pro‐inflammatory cytokines and prostanoids.Methods: Thirteen cancer patients with intractable pain caused by vertebral metastasis received 2–3 mg betamethasone in the lumbar subarachnoid space. CSF concentrations of tumor necrosis factor‐α (TNF‐α), interleukin‐1β (IL‐1β), IL‐6, IL‐8 and prostaglandin E2 (PGE2) were measured with an enzyme‐linked immunosorbent assay (ELISA) and a chemiluminescence enzyme immunoassay. Pain was measured using a numerical pain score (range, 0–10; 0, no pain; 10, worst pain imaginable).Results: Intrathecal betamethasone was associated with a significant decrease in the pain score in six patients. In these cases, the pain score decreased from 6.7 ± 0.5 (mean ± standard error of the mean) to 3.3 ± 0.3 (P < 0.05), and the CSF concentrations of IL‐8 and PGE2 decreased significantly compared with pre‐treatment levels (IL‐8, 183.3 ± 21.2 to 116.5 ± 10.6 pg/ml; PGE2, 43.8 ± 10.3 to 14.7 ± 3.0 pg/ml). There were no significant changes in the CSF concentrations of cytokines and PGE2 in the remaining seven patients.Conclusion: Pain relief with intrathecal betamethasone is related to decreases in the CSF concentration of IL‐8 and PGE2.
- 14 March 2007
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 51 (4) , 490-494
Intrathecal betamethasone pain relief in cancer patients with vertebral metastasis: a pilot study*
Background: We have reported previously the usefulness of intrathecal betamethasone for pain relief in cancer patients who suffer from intractable pain caused by vertebral metastasis. The mechanism by which betamethasone relieves pain may be related to alterations in cerebrospinal fluid (CSF) concentrations of pro‐inflammatory cytokines and prostanoids.Methods: Thirteen cancer patients with intractable pain caused by vertebral metastasis received 2–3 mg betamethasone in the lumbar subarachnoid space. CSF concentrations of tumor necrosis factor‐α (TNF‐α), interleukin‐1β (IL‐1β), IL‐6, IL‐8 and prostaglandin E2 (PGE2) were measured with an enzyme‐linked immunosorbent assay (ELISA) and a chemiluminescence enzyme immunoassay. Pain was measured using a numerical pain score (range, 0–10; 0, no pain; 10, worst pain imaginable).Results: Intrathecal betamethasone was associated with a significant decrease in the pain score in six patients. In these cases, the pain score decreased from 6.7 ± 0.5 (mean ± standard error of the mean) to 3.3 ± 0.3 (P < 0.05), and the CSF concentrations of IL‐8 and PGE2 decreased significantly compared with pre‐treatment levels (IL‐8, 183.3 ± 21.2 to 116.5 ± 10.6 pg/ml; PGE2, 43.8 ± 10.3 to 14.7 ± 3.0 pg/ml). There were no significant changes in the CSF concentrations of cytokines and PGE2 in the remaining seven patients.Conclusion: Pain relief with intrathecal betamethasone is related to decreases in the CSF concentration of IL‐8 and PGE2.
- Open Access
- 1 November 2006
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 39 (11) , 1425-1434
Inducible nitric oxide synthase and tumor necrosis factor-alpha in delayed gastric emptying and gastrointestinal transit induced by lipopolysaccharide in mice
Gastrointestinal motility disturbances during endotoxemia are probably caused by lipopolysaccharide (LPS)-induced factors: candidates include nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin-1ß, and interleukin-6. Flow cytometry was used to determine the effects of LPS and these factors on gastric emptying (evaluated indirectly by determining percent gastric retention; %GR) and gastrointestinal transit (GIT) in male BALB/c mice (23-28 g). NO (300 µg/mouse, N = 8) and TNF-α (2 µg/mouse, N = 7) increased (P < 0.01) GR and delayed GIT, mimicking the effect of LPS (50 µg/mouse). During early endotoxemia (1.5 h after LPS), inhibition of inducible NO synthase (iNOS) by a selective inhibitor, 1400 W (150 µg/mouse, N = 11), but not antibody neutralization of TNF-α (200 µg/mouse, N = 11), reversed the increase of GR (%GR 78.8 ± 3.3 vs 47.2 ± 7.5%) and the delay of GIT (geometric center 3.7 ± 0.4 vs 5.6 ± 0.2). During late endotoxemia (8 h after LPS), both iNOS inhibition (N = 9) and TNF-α neutralization (N = 9) reversed the increase of GR (%GR 33.7 ± 2.0 vs 19.1 ± 2.6% (1400 W) and 20.1 ± 2.0% (anti-TNF-α)), but only TNF-α neutralization reversed the delay of GIT (geometric center 3.9 ± 0.4 vs 5.9 ± 0.2). These findings suggest that iNOS, but not TNF-α, is associated with delayed gastric emptying and GIT during early endotoxemia and that during late endotoxemia, both factors are associated with delayed gastric emptying, but only TNF-α is associated with delayed GIT.
- 1 November 2006
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 39 (11) , 1425-1434
Open AccessInducible nitric oxide synthase and tumor necrosis factor-alpha in delayed gastric emptying and gastrointestinal transit induced by lipopolysaccharide in mice
Gastrointestinal motility disturbances during endotoxemia are probably caused by lipopolysaccharide (LPS)-induced factors: candidates include nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin-1ß, and interleukin-6. Flow cytometry was used to determine the effects of LPS and these factors on gastric emptying (evaluated indirectly by determining percent gastric retention; %GR) and gastrointestinal transit (GIT) in male BALB/c mice (23-28 g). NO (300 µg/mouse, N = 8) and TNF-α (2 µg/mouse, N = 7) increased (P < 0.01) GR and delayed GIT, mimicking the effect of LPS (50 µg/mouse). During early endotoxemia (1.5 h after LPS), inhibition of inducible NO synthase (iNOS) by a selective inhibitor, 1400 W (150 µg/mouse, N = 11), but not antibody neutralization of TNF-α (200 µg/mouse, N = 11), reversed the increase of GR (%GR 78.8 ± 3.3 vs 47.2 ± 7.5%) and the delay of GIT (geometric center 3.7 ± 0.4 vs 5.6 ± 0.2). During late endotoxemia (8 h after LPS), both iNOS inhibition (N = 9) and TNF-α neutralization (N = 9) reversed the increase of GR (%GR 33.7 ± 2.0 vs 19.1 ± 2.6% (1400 W) and 20.1 ± 2.0% (anti-TNF-α)), but only TNF-α neutralization reversed the delay of GIT (geometric center 3.9 ± 0.4 vs 5.9 ± 0.2). These findings suggest that iNOS, but not TNF-α, is associated with delayed gastric emptying and GIT during early endotoxemia and that during late endotoxemia, both factors are associated with delayed gastric emptying, but only TNF-α is associated with delayed GIT.
- 1 January 2005
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 27 (3) , 357-369
Effect of Subhypnotic Doses of Dexmedetomidine on Antitumor Immunity in Mice
Dexmedetomidine, a selective α2 adrenergic receptor agonist, is a drug often used for sedation. Despite the high prevalence of sedating patients with tumors in intensive care settings, little is known about the effect of sedative drugs on tumor growth. We studied the effect of dexmedetomidine on antitumor immunity in mice. Subhypnotic doses of dexmedetomidine decreased interleukin (IL)-12 production from thioglycollate-induced macrophages. The treatment also decreased the ratio of the helper T lymphocytes subsets, Th1 to Th2 (Th1/Th2), in the spleen. Following subcutaneous inoculation of EL4 T-cell lymphoma cells, dexmedetomidine further decreased the splenic Th1/Th2 ratio and activity of EL4-specific cytotoxic T lymphocytes (CTLs). Finally, treatment with dexmedetomidine accelerated EL4 growth in mice. These data show that treatment of mice with subhypnotic doses of dexmedetomidine downregulates antitumor immunity, possibly through the decreased production of IL-12 from antigen presenting cells, resulting in a Th2 shift and decreased CTL activity against EL4 in mice.
- 1 January 2005
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 27 (3) , 357-369
Effect of Subhypnotic Doses of Dexmedetomidine on Antitumor Immunity in Mice
Dexmedetomidine, a selective α2 adrenergic receptor agonist, is a drug often used for sedation. Despite the high prevalence of sedating patients with tumors in intensive care settings, little is known about the effect of sedative drugs on tumor growth. We studied the effect of dexmedetomidine on antitumor immunity in mice. Subhypnotic doses of dexmedetomidine decreased interleukin (IL)-12 production from thioglycollate-induced macrophages. The treatment also decreased the ratio of the helper T lymphocytes subsets, Th1 to Th2 (Th1/Th2), in the spleen. Following subcutaneous inoculation of EL4 T-cell lymphoma cells, dexmedetomidine further decreased the splenic Th1/Th2 ratio and activity of EL4-specific cytotoxic T lymphocytes (CTLs). Finally, treatment with dexmedetomidine accelerated EL4 growth in mice. These data show that treatment of mice with subhypnotic doses of dexmedetomidine downregulates antitumor immunity, possibly through the decreased production of IL-12 from antigen presenting cells, resulting in a Th2 shift and decreased CTL activity against EL4 in mice.
- 1 October 2004
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 99 (4) , 1102-1106
Propofol and Midazolam Inhibit Gastric Emptying and Gastrointestinal Transit in Mice
We studied the effect of propofol and midazolam on gastric emptying and gastrointestinal transit in mice. Ten minutes after intraperitoneal injection of propofol or midazolam, 0.2 mL of saline containing fluorescent microbeads was infused into the stomach. Thirty minutes later, the gastrointestinal tract was excised, and gastric emptying and gastrointestinal transit were calculated by measuring the quantity of fluorescent microbeads in the gastrointestinal tract by using a flow cytometer. At a dose that produced a light level of sedation (mice righted themselves within 2 s), both drugs significantly, but weakly, inhibited gastric emptying to a similar degree (propofol: P < 0.001 versus control value; 95% confidence interval [CI] for difference, 4.9%-20.2%; midazolam: P < 0.001 versus control value; 95% CI for difference, 7.8%-14.7%). Midazolam, but not propofol, delayed gastrointestinal transit (P < 0.001). At a larger dose that produced a deeper level of sedation (absence of righting reflex >10 s), both drugs significantly inhibited gastric emptying (propofol: P < 0.001; 95% CI for difference, 31.4%-61.2%; midazolam: P < 0.001; 95% CI for difference, 30.8%-61.1%) and gastrointestinal transit (P < 0.001 for both drugs).
- 1 October 2004
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 99 (4) , 1102-1106
Propofol and Midazolam Inhibit Gastric Emptying and Gastrointestinal Transit in Mice
We studied the effect of propofol and midazolam on gastric emptying and gastrointestinal transit in mice. Ten minutes after intraperitoneal injection of propofol or midazolam, 0.2 mL of saline containing fluorescent microbeads was infused into the stomach. Thirty minutes later, the gastrointestinal tract was excised, and gastric emptying and gastrointestinal transit were calculated by measuring the quantity of fluorescent microbeads in the gastrointestinal tract by using a flow cytometer. At a dose that produced a light level of sedation (mice righted themselves within 2 s), both drugs significantly, but weakly, inhibited gastric emptying to a similar degree (propofol: P < 0.001 versus control value; 95% confidence interval [CI] for difference, 4.9%-20.2%; midazolam: P < 0.001 versus control value; 95% CI for difference, 7.8%-14.7%). Midazolam, but not propofol, delayed gastrointestinal transit (P < 0.001). At a larger dose that produced a deeper level of sedation (absence of righting reflex >10 s), both drugs significantly inhibited gastric emptying (propofol: P < 0.001; 95% CI for difference, 31.4%-61.2%; midazolam: P < 0.001; 95% CI for difference, 30.8%-61.1%) and gastrointestinal transit (P < 0.001 for both drugs).
- 16 September 2004
- Published by Wiley in Anaesthesia
- Vol. 59 (10) , 954-959
Effect of propofol and isoflurane anaesthesia on the immune response to surgery*
Summary: There are two major subpopulations of peripheral helper T lymphocytes: T helper 1 (Th1) and T helper 2 (Th2) cells. Surgical stress increases the number of Th2 cells, and decreases that of Th1 cells, resulting in a decrease in the Th1/Th2 ratio, and, consequently, in suppressed cell‐mediated immunity. Since anaesthesia can suppress the stress response to surgery, it may inhibit the decrease in the Th1/Th2 ratio. Using flow cytometry, we studied whether propofol anaesthesia ( n = 9) or isoflurane anaesthesia ( n = 9) had more effect on the decrease in the Th1/Th2 ratio after surgery in patients undergoing craniotomy. The Th1/Th2 ratio decreased significantly after isoflurane anaesthesia ( p = 0.011), while it did not change after propofol anaesthesia. The ratio was significantly lower with isoflurane than propofol ( p = 0.009). Propofol anaesthesia attenuated the surgical stress‐induced adverse immune response better than isoflurane anaesthesia.
- 16 September 2004
- Published by Wiley in Anaesthesia
- Vol. 59 (10) , 954-959
Effect of propofol and isoflurane anaesthesia on the immune response to surgery*
Summary: There are two major subpopulations of peripheral helper T lymphocytes: T helper 1 (Th1) and T helper 2 (Th2) cells. Surgical stress increases the number of Th2 cells, and decreases that of Th1 cells, resulting in a decrease in the Th1/Th2 ratio, and, consequently, in suppressed cell‐mediated immunity. Since anaesthesia can suppress the stress response to surgery, it may inhibit the decrease in the Th1/Th2 ratio. Using flow cytometry, we studied whether propofol anaesthesia ( n = 9) or isoflurane anaesthesia ( n = 9) had more effect on the decrease in the Th1/Th2 ratio after surgery in patients undergoing craniotomy. The Th1/Th2 ratio decreased significantly after isoflurane anaesthesia ( p = 0.011), while it did not change after propofol anaesthesia. The ratio was significantly lower with isoflurane than propofol ( p = 0.009). Propofol anaesthesia attenuated the surgical stress‐induced adverse immune response better than isoflurane anaesthesia.
- 1 September 2004
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 54 (09) , 557-562
A New Method Using Flow Cytometry to Measure the Effects of Drugs on Gastric Emptying and Gastrointestinal Transit in Mice
The use of radiolabelled markers is considered to be a gold standard for assessing gastric emptying and gastrointestinal transit in mice and rats, but their use has increasingly been restricted due to health concern. Therefore, a new method using fluorescent polystyrene microbeads and flow cytometry was devised. Saline containing fluorescent markers (together with non-fluorescent microbeads) was infused into the stomach of each mouse and gastric emptying and gastrointestinal transit were calculated by measuring the quantity of the fluorescent microbeads in the gastrointestinal tract using flow cytometer. The effects of saline (as a control), morphine (CAS 52-26-6) and dexmedetomidine (CAS 113775-47-6) were tested. Both gastric emptying and gastrointestinal transit measured with this method (after i.p. injection of saline) were similar to those reported previously using the conventional radiolabelled methods. Morphine significantly inhibited both gastric emptying and gastrointestinal transit in a dose-dependent manner. Dexmedetomidine did not significantly inhibit gastric emptying but inhibited gastrointestinal transit. These results were also similar to those obtained using the conventional radio-labelled method. The method using fluorescent microbeads and flow cytometry may be a reliable alternative to the methods using radioisotope for studying the effects of drugs on gastric emptying and gastrointestinal transit. Eine neue flußzytometrische Methode zur Messung der Wirkungen von Arzneistoffen auf die Magenentleerung und die Magen-Darm-Passage bei Mäusen Die Verwendung radoaktiver Marker gilt als Goldstandard für die Bewertung der Magenentleerung und der Magen-Darm-Passage bei Mäusen und Ratten. Allerdings werden sie aus gesundheitlichen Gründen immer weniger eingesetzt. Deshalb wurde eine neue flußzytometrische Methode auf der Basis fluoreszierender Polystyren-Mikrokügelchen entwickelt. Kochsalzlösung mit fluoreszierenden Markern wurde (zusammen mit nichtfluoreszierenden Mikrokügelchen) in den Magen der Mäuse infundiert, und die Magenentleerung und Magen-Darm-Passage wurden durch Quantifizierung der fluoreszierenden Mikrokügelchen im Magen-Darm-Trakt flußzytometrisch ermittelt. Es wurde die Wirkung von Kochsalzlösung (als Kontrolle), Morphin (CAS 52-26-6) und Dexmedetomidin (CAS 113775-47-6) untersucht. Sowohl die Magenentleerung als auch die Magen-Darm-Passage, die auf diese Weise (nach i.p. Injektion von Kochsalzlösung) ermittelt wurden, waren mit denen nach der herkömmlichen Methode mit radioaktiven Markern gemessenen identisch. Dexmedetomidin hemmte die Magenentleerung nicht signifikant, hemmte aber die Magen-Darm-Passage. Diese Ergebnisse entsprachen ebenfalls jenen der herkömmlichen Methode mit radioaktiven Markern. Die flußzytometrische Methode auf der Basis fluoreszierender Mikrokügelchen kann als verläßliche Alternative zu den Methoden mit Radioisotopen angesehen werden, um die Wirkung von Arzneistoffen auf die Magenentleerung und die Magen-Darm-Passage zu untersuchen.
- 1 September 2004
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 54 (09) , 557-562
A New Method Using Flow Cytometry to Measure the Effects of Drugs on Gastric Emptying and Gastrointestinal Transit in Mice
The use of radiolabelled markers is considered to be a gold standard for assessing gastric emptying and gastrointestinal transit in mice and rats, but their use has increasingly been restricted due to health concern. Therefore, a new method using fluorescent polystyrene microbeads and flow cytometry was devised. Saline containing fluorescent markers (together with non-fluorescent microbeads) was infused into the stomach of each mouse and gastric emptying and gastrointestinal transit were calculated by measuring the quantity of the fluorescent microbeads in the gastrointestinal tract using flow cytometer. The effects of saline (as a control), morphine (CAS 52-26-6) and dexmedetomidine (CAS 113775-47-6) were tested. Both gastric emptying and gastrointestinal transit measured with this method (after i.p. injection of saline) were similar to those reported previously using the conventional radiolabelled methods. Morphine significantly inhibited both gastric emptying and gastrointestinal transit in a dose-dependent manner. Dexmedetomidine did not significantly inhibit gastric emptying but inhibited gastrointestinal transit. These results were also similar to those obtained using the conventional radio-labelled method. The method using fluorescent microbeads and flow cytometry may be a reliable alternative to the methods using radioisotope for studying the effects of drugs on gastric emptying and gastrointestinal transit. Eine neue flußzytometrische Methode zur Messung der Wirkungen von Arzneistoffen auf die Magenentleerung und die Magen-Darm-Passage bei Mäusen Die Verwendung radoaktiver Marker gilt als Goldstandard für die Bewertung der Magenentleerung und der Magen-Darm-Passage bei Mäusen und Ratten. Allerdings werden sie aus gesundheitlichen Gründen immer weniger eingesetzt. Deshalb wurde eine neue flußzytometrische Methode auf der Basis fluoreszierender Polystyren-Mikrokügelchen entwickelt. Kochsalzlösung mit fluoreszierenden Markern wurde (zusammen mit nichtfluoreszierenden Mikrokügelchen) in den Magen der Mäuse infundiert, und die Magenentleerung und Magen-Darm-Passage wurden durch Quantifizierung der fluoreszierenden Mikrokügelchen im Magen-Darm-Trakt flußzytometrisch ermittelt. Es wurde die Wirkung von Kochsalzlösung (als Kontrolle), Morphin (CAS 52-26-6) und Dexmedetomidin (CAS 113775-47-6) untersucht. Sowohl die Magenentleerung als auch die Magen-Darm-Passage, die auf diese Weise (nach i.p. Injektion von Kochsalzlösung) ermittelt wurden, waren mit denen nach der herkömmlichen Methode mit radioaktiven Markern gemessenen identisch. Dexmedetomidin hemmte die Magenentleerung nicht signifikant, hemmte aber die Magen-Darm-Passage. Diese Ergebnisse entsprachen ebenfalls jenen der herkömmlichen Methode mit radioaktiven Markern. Die flußzytometrische Methode auf der Basis fluoreszierender Mikrokügelchen kann als verläßliche Alternative zu den Methoden mit Radioisotopen angesehen werden, um die Wirkung von Arzneistoffen auf die Magenentleerung und die Magen-Darm-Passage zu untersuchen.
- 1 February 2001
- Published by Wolters Kluwer Health
- Vol. 92 (2) , 362-368
Xenon Inhibits but N2O Enhances Ketamine-Induced c-Fos Expression in the Rat Posterior Cingulate and Retrosplenial Cortices
Both nitrous oxide (N2O) and xenon are N-methyl-d-aspartate receptor antagonists that have psychotomimetic effects and cause neuronal injuries in the posterior cingulate and retrosplenial cortices. We investigated the effect of xenon, xenon with ketamine, N2O, and N2O with ketamine on c-Fos expression in the rat posterior cingulate and retrosplenial cortices, a marker of psychotomimetic effects. Brain sections were prepared, and c-Fos expression was detected with immunohistochemical methods. A loss of microtubule-associated protein 2, a marker of neuronal injury, was also investigated. The number of Fos-like immunoreactivity positive cells by ketamine IV at a dose of 5 mg/kg under 70% N2O (128 ± 12 cells per 0.5 mm2) was significantly more than those under 30% (15 ± 2 cells per 0.5 mm2) and 70% xenon (2 ± 1 cells per 0.5 mm2). Despite differences in c-fos immunoreactivity, there was no loss of microtubule-associated protein 2 immunoreactivity in any group examined. Xenon may suppress the adverse neuronal effects of ketamine, and combined use of xenon and ketamine seems to be safe in respect to neuronal adverse effects. Implications Xenon may suppress adverse neuronal effects of ketamine. Conversely, combined use of N2O and ketamine may increase the risk of neuronal adverse effects, such as psychotomimetic effects.
- 1 February 2001
- Published by Wolters Kluwer Health
- Vol. 92 (2) , 362-368
Xenon Inhibits but N2O Enhances Ketamine-Induced c-Fos Expression in the Rat Posterior Cingulate and Retrosplenial Cortices
Both nitrous oxide (N2O) and xenon are N-methyl-d-aspartate receptor antagonists that have psychotomimetic effects and cause neuronal injuries in the posterior cingulate and retrosplenial cortices. We investigated the effect of xenon, xenon with ketamine, N2O, and N2O with ketamine on c-Fos expression in the rat posterior cingulate and retrosplenial cortices, a marker of psychotomimetic effects. Brain sections were prepared, and c-Fos expression was detected with immunohistochemical methods. A loss of microtubule-associated protein 2, a marker of neuronal injury, was also investigated. The number of Fos-like immunoreactivity positive cells by ketamine IV at a dose of 5 mg/kg under 70% N2O (128 ± 12 cells per 0.5 mm2) was significantly more than those under 30% (15 ± 2 cells per 0.5 mm2) and 70% xenon (2 ± 1 cells per 0.5 mm2). Despite differences in c-fos immunoreactivity, there was no loss of microtubule-associated protein 2 immunoreactivity in any group examined. Xenon may suppress the adverse neuronal effects of ketamine, and combined use of xenon and ketamine seems to be safe in respect to neuronal adverse effects. Implications Xenon may suppress adverse neuronal effects of ketamine. Conversely, combined use of N2O and ketamine may increase the risk of neuronal adverse effects, such as psychotomimetic effects.